$SILO News

Last published 1mo ago

1mo agoSILOSilo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property PortfolioGlobeNewswireAllowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the
2mo agoSILOSilo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation ForumGlobeNewswireSARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), "), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug
2mo agoSILOSilo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD TreatmentGlobeNewswireFollows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program SARASOTA, FLA., Aug. 18, 2026 (GLOBE NEWSWIRE) --
3mo agoSILOSilo Pharma Granted European Patent Covering Novel PTSD TherapyGlobeNewswirePatent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop SARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma
3mo agoSILOSilo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI PlatformGlobeNewswireCollaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption SARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma
3mo agoSILOSilo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug ProgramGlobeNewswireSilo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate AI agent platform prepares for commercial launch while SPC-15 regulatory program advances
4mo agoSILOSilo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent PlatformGlobeNewswireSARASOTA, FLA., July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on
4mo agoSILOSilo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswire$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash SARASOTA, FLA., July 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.
4mo agoSILOSilo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer ProgramGlobeNewswireSARASOTA, FLA., July 07, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on
4mo agoSILOSilo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting RequestGlobeNewswireStudy designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system SARASOTA, FLA., June 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the
4mo agoSILOSilo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical TrialGlobeNewswirePositive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or
4mo agoSILOSilo Pharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireSARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today
6mo agoSILOSilo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain InjuryGlobeNewswireNew initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved therapies
6mo agoSILOSilo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDGlobeNewswireFederal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.
6mo agoSILOSilo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, QwikagentsGlobeNewswireLaunch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the
6mo agoSILOSilo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon PsychedelicsGlobeNewswireSPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), a developmental-stage
7mo agoSILOSilo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention TherapyGlobeNewswireEPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the
8mo agoSILOSilo Pharma Announces Share Buyback ProgramGlobeNewswireSarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research,
8mo agoSILOSilo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property PortfolioGlobeNewswireSARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery
10mo agoSILOSilo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15GlobeNewswirePlanned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified
11mo agoSILOSilo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSDGlobeNewswireSARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that
1y agoSILOSilo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana BlockchainGlobeNewswireInvestment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility Strategic allocation aligns with Silo's objective of generating yield while maintaining a hedge against
1y agoSILOSilo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury ProgramGlobeNewswireSignificant milestones are approaching in drug development; additional digital asset purchases expected Preparation for FDA IND application expected to commence before year-end SARASOTA, FL, Oct. 23, 2025 (GLOBE
1y agoSILOSilo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain GrowthGlobeNewswireSARASOTA, FL, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its
1y agoSILOSilo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)GlobeNewswireCompany invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) --
1y agoSILOSilo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireSARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery
1y agoSILOSilo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireSARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery
1y agoSILOSilo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury ManagementGlobeNewswireFireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date
1y agoSILOSilo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and SecurityGlobeNewswireSARASOTA, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that
1y agoSILOSilo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury StrategyGlobeNewswireStrategic capital deployment advances Company's blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the
1y agoSILOSilo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD DrugGlobeNewswireSARASOTA, FL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that
1y agoSILOSilo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP PortfolioGlobeNewswireSARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that
1y agoSILOSilo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed JournalGlobeNewswireManuscript featured in leading open-access scientific journal Alzheimer's Research & Therapy SARASOTA, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a
1y agoSILOSilo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) PathwayGlobeNewswireSPC-15's intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified
1y agoSILOSilo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury PlatformGlobeNewswireTargeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency
1y agoSILOSilo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15GlobeNewswireSARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today
1y agoSILOSilo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025GlobeNewswirePlanned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15
1y agoHOTH SILOSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketGlobeNewswireTechnology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage
1y agoHOTH SILOHoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.PR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the formation of a strategic joint venture to develop and ...
1y agoSILOSilo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsGlobeNewswireSARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today
1y agoSILOSilo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve AssetGlobeNewswireSARASOTA, FL, June 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today
1y agoSILOSilo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15GlobeNewswireSARASOTA, FL, May 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today
1y agoSILOSilo Pharma Announces Closing of $2 Million Public OfferingGlobeNewswireSARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed
1y agoSILOSilo Pharma Announces Pricing of $2 Million Public OfferingGlobeNewswireSARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today
1y agoSILOSilo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15GlobeNewswireSARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today
1y agoSILOSilo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage LaboratoriesGlobeNewswireSARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today
1y agoSILOSilo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia StudyGlobeNewswire— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo," or the "Company"), a developmental stage
1y agoSILOSilo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's DrugGlobeNewswireSARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today
1y agoSILOSilo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD TreatmentGlobeNewswirePreclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage
1y agoSILOSilo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder TreatmentGlobeNewswireSARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today